Myasthenia gravis
Disease-a-Month, ISSN: 0011-5029, Vol: 36, Issue: 11, Page: 599-637
1990
- 16Citations
- 21Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Myasthenia Gravis is a disorder of neuromuscular function resulting from an immunologically based premature destruction of acetylcholine receptors. The disease is characterized clinically by variable weakness accentuated by repetitive muscular activity and usually responding to the administration of acetylcholinesterase inhibitors. Myasthenia Gravis is a complex disease and requires understanding of the many facets of its natural history and immunological basis to ensure optimal individual patient management. The long-term goal is control of the immunological. imbalance; treatment regimens include thymectomy, corticosteroids, azathioprine, and plasmapheresis. The common use of acetylcholinesterase inhibitors provides symptomatic relief during variable daily muscular activity. Disability due to myasthenia gravis is to a large extent reversible and death is preventable. Early recognition of myasthenia gravis and appropriate treatment are often rewarded by remission that may be permanent.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/001150299090006D; http://dx.doi.org/10.1016/0011-5029(90)90006-d; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0025514104&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/2209357; http://linkinghub.elsevier.com/retrieve/pii/001150299090006D; http://api.elsevier.com/content/article/PII:001150299090006D?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:001150299090006D?httpAccept=text/plain; https://linkinghub.elsevier.com/retrieve/pii/001150299090006D; http://dx.doi.org/10.1016/0011-5029%2890%2990006-d; https://dx.doi.org/10.1016/0011-5029%2890%2990006-d
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know